Jiangsu Shengsi Biopharmaceutical

Jiangsu Shengsi Biopharmaceutical is a clinical-stage biotechnology company based in China, dedicated to the research, development, and industrialization of recombinant protein therapeutics. The company primarily focuses on hematology and rare diseases, specifically developing long-acting coagulation factors for the treatment of Hemophilia A and B. Its lead product, SS109, is a recombinant human coagulation factor VIIa currently in Phase 3 clinical trials for patients with hemophilia who have developed inhibitors. Shengsi utilizes proprietary protein engineering platforms to enhance the pharmacokinetic profiles of its biologics, aiming to reduce the treatment burden for patients. The company operates out of the China Medical City in Taizhou, maintaining integrated R&D and manufacturing capabilities. By focusing on high-barrier recombinant products, Shengsi aims to provide domestic alternatives to expensive imported blood-derived and recombinant therapies in the Chinese market.